Conmed (NASDAQ: CNMD) reported Q2 EPS of $0.36, $0.08 worse than the analyst estimate of $0.44. Revenue for the quarter came in at $181 million versus the consensus estimate of $182.6 million.

2015 Outlook

The Company reiterated its previously disclosed constant currency sales guidance, which calls for organic sales growth in 2015 to be in the range of 1% to 3%. Using current exchange rates, CONMED continues to anticipate that reported sales for 2015 will be in the range of $723 million to $738 million, representing a growth range of (2%) to 0%, and that adjusted diluted net earnings per share will be in the range of $1.82 to $1.92.

For earnings history and earnings-related data on Conmed (CNMD) click here.